Use of a standardized MxA protein measurement-based assay for validation of assays for the assessment of neutralizing antibodies against interferon-β - PubMed (original) (raw)

. 2013 Nov;33(11):660-71.

doi: 10.1089/jir.2012.0079. Epub 2013 Jul 13.

Meena Subramanyam, Susan Goelz, Jaya Goyal, Vijay Jethwa, Wendy Jones, James G Files, Daniel Kramer, Chris Bird, Paula Dilger, Michael Tovey, Christophe Lallemand, Robin Thorpe

Affiliations

Use of a standardized MxA protein measurement-based assay for validation of assays for the assessment of neutralizing antibodies against interferon-β

Meenu Wadhwa et al. J Interferon Cytokine Res. 2013 Nov.

Abstract

Effective monitoring of the development of neutralizing antibodies (NAbs) against IFN-β in multiple sclerosis (MS) patients on IFN-β therapy is important for clinical decision making and disease management. To date, antiviral assays have been the favored approach for NAb determination, but variations in assay conditions between laboratories and the increasing use of novel assays have contributed to the reporting of inconsistent antibody data between laboratories and between products. This study, undertaken at the request of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), is a joint effort by manufacturers of IFN-β products (approved in Europe) towards harmonization of a NAb assay that facilitates generation of comparable NAb data, which, in conjunction with clinical outcomes, should prove useful for clinicians treating MS patients with IFN-β products. This article describes the standardized cellular myxovirus resistance protein A (MxA) protein measurement-based assay for detection of IFN-β NAbs and its use for the validation of assays used for the quantitative determination of such antibodies. Although titers varied between laboratories and the products used, utilization of IFN-β1a rather than IFN-β1b as the challenge antigen produced more consistent results in the NAb assay. Adoption of the standardized assay improves comparability between laboratories circumventing problems that arise when different, nonstandardized assays are employed for immunogenicity assessment. Based on the data, the EMA recommended for standardization purposes, the use of IFN-β1a in NAb assays, independent of the therapeutic product used for therapy and validation of new NAb procedures against the standardized assay described.

PubMed Disclaimer

Figures

FIG. 1.

FIG. 1.

IFN-β NAb titers in antibody-positive patient sera using different antibody pairs in MxA ELISA for determination of MxA protein. IFN-β1a was used as the challenge antigen in the MxA assay; using Pearson's correlation, r=0.994 (_n_=28 for antibody-positive samples; _n_=31 in total). MxA, myxovirus resistance protein A; Nab, neutralizing antibody.

FIG. 2.

FIG. 2.

IFN-β NAb titers for antibody-positive patient sera using the MxA and luciferase NAb assays. (A) Using IFN-β1a as the challenge antigen (_n_=52 in total), the Pearson's correlation, r=0.951 for the antibody-positive samples (_n_=32). (B) Using IFN-β1b as the challenge antigen (_n_=65 in total), the Pearson's correlation, r=0.906 for the antibody-positive samples (_n_=45).

Similar articles

Cited by

References

    1. Aarskog N. Marøy T. Myhr K. Vedeler C. Antibodies against interferon-beta in multiple sclerosis. J Neuroimmunol. 2009;212:148–150. - PubMed
    1. Bertolotto A. Implications of neutralising antibodies on therapeutic efficacy. J Neurol Sci. 2009;277(Suppl 1):S29–S32. - PubMed
    1. Bertolotto A. Deisenhammer F. Gallo P. Sölberg Sørensen P. Immunogenicity of interferon beta: differences among products. J Neurol. 2004;251(Suppl 2):II15–II24. - PubMed
    1. Bertolotto A. Gilli F. Sala A. Capobianco M. Malucchi S. Milano E. Melis F. Marnetto F. Lindberg RL. Bottero R. Di Sapio A. Giordana MT. Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients. Neurology. 2003;60:634–639. - PubMed
    1. Bertolotto A. Sala A. Caldano M. Capobianco M. Malucchi S. Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta. J Immunol Methods. 2007;321:19–31. others. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources